J&J's Evra Canadian Label Includes Obesity, Sauna Warnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling on risk of venous thromboembolism associated with the birth control patch in Canada appears stronger than FDA's revision on Ortho Evra.
You may also be interested in...
Ortho Evra Label Update Includes Study Data On Blood Clot Risk
FDA requests J&J conduct longer follow up studies on the risk of serious blood clots, heart attack and stroke associated with the birth control patch.
Ortho-McNeil Conducting Additional Studies To Assess Ortho Evra Blood Clotting Risks
The firm updated labeling to include a new bolded warning regarding increased hormone exposure with the patch versus oral contraceptives.
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
Company plans a "Dear Doctor" letter informing U.S. physicians of Health Canada's decision. FDA says it "has not decided to take any further regulatory action at this time"; sudden death warnings were added to Adderall XR's labeling in August.